Junior IT Systems Administrator

PSI CRO to present agile models for emerging biotech at OCT New England. Ninety-three percent repeat business and 15% revenue growth in a single year puts PSI CRO in an unusual position for a mid-size CRO: sponsors keep coming back, which suggests the agility argument it plans to make at OCT New England next week is grounded in something operational rather than just a conference pitch. On October 27 at Encore Boston Harbor in Boston, Benjamin Raccanova, PSI's Head of Business Oversight, joins Stream C of the 18th Annual Outsourcing in Clinical Trials New England conference for a peer-driven session on how small and emerging biotech sponsors can hold onto operational control while scaling global programs. The pressure point is real: investor timelines, regulatory scrutiny, and the site-level complexity introduced by the FDA's 2024 final guidance on decentralized clinical trials all pull in different directions for a sponsor that doesn't have a 500-person clinical operations team to absorb the friction. The debate framing matters here. Raccanova's panel asks directly whether large CRO operating models are equipped to serve emerging biotech, which sets up a structural question that PSI has a commercial interest in answering a particular way, but also has data to back up. In 2024, 93% of PSI's studies enrolled on time or ahead of schedule. For a biotech sponsor burning cash against a runway, a slip in enrollment doesn't just delay a readout, it often triggers a bridge financing conversation. The session runs at 3:15 PM on October 27. Whether the peer discussion produces anything transferable beyond the room will depend on how many attending sponsors are willing to describe what broke in their last CRO relationship out loud. That candor, not the panel format itself, is what tends to make these conversations useful.

From Shanghai to Beijing: PSI CRO expands its footprint in China with a new Beijing office. Beijing, China - April 28, 2026 - PSI CRO, a Swiss-based global full-service contract research organization, today announced the opening of its second office in China, located in China World Tower B in Beijing's Chaoyang District. In 2019, PSI established its first China office in Shanghai, where the local team has steadily grown while supporting sponsors across the region. By adding a Beijing location, PSI brings its team closer to key drug regulatory authorities and leading research institutions. China is playing an increasingly important role in global clinical development, creating a growing need for strong local operational and regulatory support. PSI's presence in Beijing helps meet that need, combining local expertise with coordinated global teams to support clear decision-making and predictable, on-time delivery for sponsors. For PSI, the Beijing office represents a targeted investment to support clients where it matters most - close to regulators, close to investigator sites, and close to strategic partners.